
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In add... Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -21.48 | -4.44646849383 | 483.08 | 483.08 | 446 | 1399497 | 462.41693724 | CS |
4 | 38.87 | 9.1949944409 | 422.73 | 491.805 | 419.27 | 1581186 | 455.64210528 | CS |
12 | 7.3 | 1.60686770856 | 454.3 | 491.805 | 377.85 | 1639782 | 435.58008388 | CS |
26 | -2.95 | -0.635023140674 | 464.55 | 519.88 | 377.85 | 1344948 | 454.43845032 | CS |
52 | 43.22 | 10.3303217171 | 418.38 | 519.88 | 377.85 | 1226660 | 449.92136126 | CS |
156 | 227.85 | 97.4759358289 | 233.75 | 519.88 | 225.28 | 1329071 | 357.45395813 | CS |
260 | 220.57 | 91.5114301124 | 241.03 | 519.88 | 176.36 | 1560613 | 292.13752154 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.